Hólyagrák: vizsgálatok itt: Franciaország
70 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 2026. november 11.. Ask the study team whether a trial fits you.
- 3. fázisNot yet taking people in FranciaországA Phase 3 Open-Label, Randomized Controlled Trial of T-bren (BL-M07D1) vs. Platinum-based Chemotherapy in Patients with HER2-expressing metastatic urothelial cancer with disease progression on or after anti-PD-(L)1-based therapy
- Where
- Angers, Bordeaux, Brest, Clermont Ferrand Cedex1, Nantes Cedex 2, Paris, Rennes Cedex, Saint-Herblain Cedex, Strasbourg Cedex 2, Suresnes, Vandoeuvre Les Nancy_ Cedex, Villejuif
- Életkor
- 18 év and over
- People
- 203 worldwide
- Run by
- Systimmune Inc.
See details and how to join2026-527617-29-00 · EU 2026-527617-29-00 - 1/2. fázisTaking peopleA Clinical Study of MK-3120 in People With Bladder Cancer (MK-3120-003)
- Where
- Villejuif
- Életkor
- 18 év and over
- People
- 45 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT07222488 · EU 2025-520467-40-00 - 3. fázisTaking peopleA Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)
- Where
- Amiens Cedex 1, Bordeaux, Brest, Clermont Ferrand Cedex1, Creteil Cedex, Dijon, Lyon, Nice Cedex 2, Nimes Cedex 9, Paris, Rennes Cedex, Villejuif
- Életkor
- 18 év and over
- People
- 590 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT07419295 · EU 2024-520014-22-00 - No phaseTaking peopleEvaluation of the Clinical Utility of Online Adaptive Radiotherapy in Bladder Cancer (BLADAPT-GETUG V11)
- Where
- Avignon, Dijon, Lille, Montpellier, Paris, Rennes, Rouen, Saint-Cloud, Saint-Herblain, Toulon, Villeurbanne
- Életkor
- 18 év and over
- People
- 120
- Run by
- Institut du Cancer de Montpellier - Val d'Aurelle
See details and how to joinNCT07043543 - 1. fázisTaking peopleA Study to Learn About the Study Medicine PF-08052667 in People With Bladder Cancer
- Where
- Paris, Villejuif
- Életkor
- 18 év and over
- People
- 294 worldwide
- Run by
- Pfizer
See details and how to joinNCT07206225 · EU 2025-521756-39-00 - 1. fázisTaking peopleFORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3
- Where
- Bordeaux, Lyon, Villejuif
- Életkor
- 18 év and over
- People
- 677 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT05614739 · EU 2022-502755-59-00 - 1. fázisTaking peopleA Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
- Where
- Villejuif
- Életkor
- 18 év and over
- People
- 460 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT06465069 · EU 2024-512927-36-00 - 2. fázisTaking peopleA Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
- Where
- Bordeaux, Brest, Lille, Montpellier, Pierre-Bénite, Villejuif
- Életkor
- 18 év and over
- People
- 111 worldwide
- Run by
- Bayer
See details and how to joinNCT06760819 · EU 2024-517419-62-00 - 3. fázisTaking peopleA Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer
- Where
- Lille, Limoges, Lyon, Marseille, Paris, Quint-Fonsegrives, Rennes, Toulouse, Villejuif
- Életkor
- 18 év and over
- People
- 641 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT06319820 - 3. fázisTaking peopleA Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer
- Where
- Marseille, Paris, Paris Cedex 18, Quint-Fonsegrives, Saint-Grégoire, Villejuif
- Életkor
- 18 év and over
- People
- 220 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT06919965 · EU 2024-519493-39-00 - 2. fázisTaking peoplePhase 2A/B Efficacy and Safety of Dabogratinib in Participants With Low Grade Upper Tract Urothelial Carcinoma
- Where
- Bordeaux Cedex, Lille Cedex, Paris, Saint-Etienne
- Életkor
- 18 év and over
- People
- 285 worldwide
- Run by
- Tyra Biosciences, Inc
See details and how to joinNCT07265947 · EU 2025-523539-20-00 - 2. fázisTaking peopleA Study to Find Out if Enfortumab Vedotin Given With Pembrolizumab Helps People With Muscle-invasive Bladder Cancer Keep Their Bladder
- Where
- Cedex Lyon 08, Paris, Rennes, Strasbourg, Suresnes, Toulouse, Villejuif
- Életkor
- 18 év and over
- People
- 240 worldwide
- Run by
- Astellas Pharma Global Development, Inc.
See details and how to joinNCT07475806 - 3. fázisTaking peopleTrial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer
- Where
- Bordeaux, Clermont-Ferrand, Lyon Cedex 03, Nantes, Nimes Cedex 9, Paris Cedex 13, Paris Cedex 18, Pierre-Bénite, Rouen Cedex, Saint-Priest-en-Jarez, Toulouse Cedex 9
- Életkor
- 18 év and over
- People
- 454 worldwide
- Run by
- Ferring Pharmaceuticals
See details and how to joinNCT06510374 · EU 2024-512029-10-00 - 3. fázisTaking peopleA Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer
- Where
- Bordeaux, Clermont Ferrand Cedex 1, Lyon Cedex 03, Nantes, Nimes Cedex 9, Paris Cedex 13, Paris Cedex 18, Pierre-Bénite, Rennes, Saint-Priest-en-Jarez, Toulouse Cedex 9
- Életkor
- 18 év and over
- People
- 250 worldwide
- Run by
- Ferring Pharmaceuticals
See details and how to joinNCT06545955 · EU 2024-512177-27-01 - 2/3. fázisTaking peopleDato-DXd plus Carboplatin or Cisplatin versus Gemcitabine plus Carboplatin or Cisplatin in Previously Treated la/mUC.
- Where
- Amiens, Angers, Bordeaux, Bordeaux Cedex, Brest, Caen Cedex 5, Calais, Clermont Ferrand Cedex1, Creteil, Grenoble Cedex 9, La Chaussee St Victor, La Roche Sur Yon Cedex 9, Le Mans, Lyon, Marseille, Montpellier, Montpellier Cedex 5, Nantes Cedex 2, Nimes Cedex 9, Paris, Pierre-Bénite, Poitiers, Quint-Fonsegrives, Reims, Saint-Herblain Cedex, Saint-Priest-en-Jarez, Strasbourg Cedex 2, Toulouse Cedex 9, Vandoeuvre Les Nancy_ Cedex, Villejuif
- Életkor
- 18 év and over
- People
- 343 worldwide
- Run by
- Daiichi Sankyo Inc.
See details and how to join2024-516906-47-00 · EU 2024-516906-47-00 - 3. fázisTaking peopleEnfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309)
- Where
- Lille, Nîmes, Paris, Villejuif
- Életkor
- 18 év and over
- People
- 390 worldwide
- Run by
- Astellas Pharma Global Development, Inc.
See details and how to joinNCT07566156 · EU 2026-525612-34-00 - 2. fázisTaking peopleEfficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer
- Where
- Amiens, Marseille, Saint-Priest-en-Jarez
- Életkor
- 18 év and over
- People
- 90 worldwide
- Run by
- Tyra Biosciences, Inc
See details and how to joinNCT06995677 · EU 2025-521277-14-00 - 2. fázisTaking peopleA Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
- Where
- Bordeaux, Dijon, Lille, Lyon, Marseille, Nantes, Toulouse, Vandœuvre-lès-Nancy, Villejuif
- Életkor
- 18 év and over
- People
- 740 worldwide
- Run by
- Daiichi Sankyo
See details and how to joinNCT06172478 · EU 2023-507641-29-00 - 1/2. fázisTaking peopleA Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
- Where
- Besancon Cedex, Bordeaux, Bordeaux Cedex, Dijon, Lyon, Montpellier Cedex 5, Paris, Rennes Cedex, Saint-Herblain Cedex, Toulouse Cedex 9, Villejuif
- Életkor
- 18 év and over
- People
- 680 worldwide
- Run by
- Daiichi Sankyo
See details and how to joinNCT06330064 · EU 2023-509632-26-00 - 1. fázisNot yet taking people in FranciaországA phase I study of [177Lu]Lu-DWJ155 and [68Ga]Ga-DWJ155 in patients with solid tumors
- Where
- Lyon, Marseille
- Életkor
- 18 év and over
- People
- 64 worldwide
- Run by
- Novartis Pharma AG
See details and how to join2024-518348-19-00 · EU 2024-518348-19-00 - 2. fázisNot yet taking people in FranciaországMOST-Express – A phase II, multicenter, open-label, personalized medicine, tumor agnostic platform trial evaluating the anti-tumor activity of antibody-based therapies in metastatic cancer patients.
- Where
- Bordeaux, Lyon, Nice Cedex 2, Paris, Toulouse, Villejuif
- Életkor
- 18 év and over
- People
- 200
- Run by
- Centre Leon Berard
See details and how to join2025-522058-38-00 · EU 2025-522058-38-00 - 2. fázisTaking peoplePerioperative Durvalumab With Neoadjuvant ddMVAC in Patients With Muscle-Invasive Bladder Cancer (NIAGARA-2)
- Where
- Angers, Bordeaux, Bordeaux Cedex, Chambray-lès-Tours, Dijon, Lille, Lyon, Marseille, Montpellier, Nice Cedex 2, Nîmes, Paris, Pierre-Bénite, Poitiers, Quint-Fonsegrives, Rennes Cedex, Rouen Cedex, Strasbourg Cedex 2, Suresnes
- Életkor
- 18 év and over
- People
- 150 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06960577 · EU 2024-519246-75-01 - 3. fázisTaking peopleA Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
- Where
- Angers, Bordeaux, Brest, Caen, Lille, Lyon Cedex08, Marseille, Nîmes, Pierre-Bénite, Toulouse, Villejuif
- Életkor
- 18 év and over
- People
- 450 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT07218380 · EU 2025-522855-25-00 - No phaseTaking peopleBenchmarking Large Language Models Against Tumour Boards for Oncology Treatment Recommendations
- Where
- Boulogne-Billancourt, Paris
- Életkor
- 18 év and over
- People
- 100
- Run by
- Assistance Publique - Hôpitaux de Paris
See details and how to joinNCT07739121 - 1/2. fázisTaking peopleKEYMAKER-U04 Substudy 04D: A Clinical Study of New Treatments Given With Enfortumab Vedotin and Pembrolizumab in People With Urothelial Cancer (MK-3475-04D/KEYMAKER-U04)
- Where
- Bordeaux
- Életkor
- 18 év and over
- People
- 55 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT07232602 · EU 2025-522253-19-00